Fast Facts: Biosimilars
Biosimilars have been in clinical use for more than 10 years, and evidence from more than 700 million patient-days' exposure shows that approved biosimilars can be used as safely and effectively as their originator biologics. And yet concerns about these drugs persist, particularly in therapy a...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Livre numérique |
| Idioma: | Anglais |
| Publicat: |
Basel :
S. Karger
2018.
Basel : |
| Accés en línia: | https://www.karger.com/Book/Home/277615 Accès Université d'Orléans et IFPM |
| Nota: |
Karger Fast Facts |
| Autres localisations: | Voir dans le Sudoc |
| Sumari: | Biosimilars have been in clinical use for more than 10 years, and evidence from more than 700 million patient-days' exposure shows that approved biosimilars can be used as safely and effectively as their originator biologics. And yet concerns about these drugs persist, particularly in therapy areas where they are recent additions to the formulary. It is vital to address these concerns so that clinicians can prescribe biosimilars with confidence, realizing substantial cost savings and improving patient access to effective treatments. |
|---|---|
| Descripció de l’ítem: | Karger Fast Facts |
| ISBN: | 9781910797686 |
| Accés: | Accès libre pour tout établissement ou utilisateur ayant un compte sur la plateforme de l'éditeur |